Statins and adrenal androgen levels in prostate cancer: A new twist
Open Access
- 1 August 2021
- journal article
- editorial
- Published by Elsevier in EBioMedicine
- Vol. 70, 103494
Abstract
No abstract availableFunding Information
- National Cancer Institute
- US Department of Defense Prostate Cancer Research Program
This publication has 10 references indexed in Scilit:
- Atorvastatin induces adrenal androgen downshift in men with prostate cancer: A post Hoc analysis of a pilot adaptive Randomised clinical trialEBioMedicine, 2021
- Statin therapy and sex hormonesEuropean Journal of Pharmacology, 2021
- AKR1C3 (type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase): Roles in malignancy and endocrine disordersMolecular and Cellular Endocrinology, 2019
- Canonical and Noncanonical Androgen Metabolism and Activity2019
- Is the Evidence Sufficient to Recommend Statins for All Men With Prostate Cancer?Journal of Clinical Oncology, 2017
- Use of statins is associated with lower serum total and non-sex hormone-binding globulin-bound testosterone levels in male participants of the Rotterdam StudyEuropean Journal of Endocrinology, 2015
- Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate CancerJAMA Oncology, 2015
- The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trialsBMC Medicine, 2013
- Effect of Testosterone Replacement Therapy on Prostate Tissue in Men With Late-Onset HypogonadismJAMA, 2006
- The HMG-CoA reductase inhibitor simvastatin suppresses human testicular testosterone synthesis in vitro by a selective inhibitory effect on 17-ketosteroid-oxidoreductase enzyme activityThe Journal of Steroid Biochemistry and Molecular Biology, 1991